Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 26 June 2018 to Question 154637 on Haemophilia: Medical Treatments, what the value is of savings which have been made since 2004-05 for (a) factor VIII and (b) factor IX products; how those savings have been reinvested in haemophilia services; and whether those savings have accrued to the (i) the UK Government and (ii) the Northern Ireland Government.

NHS England only holds information for Factor VIII and Factor IX from 2007/8 (up to and including 2017/18). Spend inclusive of VAT over this period is in excess of £2 billion, with savings in excess of £400 million.

Through its commercial activities on all medicines, NHS England uses tendering to drive improvements in the overall value of the medicines it purchases. This approach ensures that the National Health Service as a whole is able to manage increasing demand within existing resources and make investment in approved, evidence based innovative treatments which demonstrate additional value and benefits in patient outcomes.

These figures relate to England only and we do not hold data on equivalent savings in Northern Ireland.